ARIA + Nucleate UK Present: Sculpting Innate Immunity
A one-day convening at the intersection of frontier immunology, translational science, and advancing research.
What would it take to turn innate immunity into a new therapeutic paradigm? This event brings together researchers, scientific trainees, founders, funders, and ecosystem partners to explore how emerging tools in immunology, synthetic biology, delivery, immune modelling, and AI could unlock entirely new ways to prevent and treat disease.
Why now?
We are at a moment when innate immunity is moving from deep research to strategic frontier. Advances in immune profiling, synthetic biology, drug delivery, organoid and tissue models, and AI-enabled discovery are creating new possibilities for precise intervention. Researchers and trainees are increasingly looking for pathways to translate high-potential science into companies, platforms, and therapies. ARIA’s opportunity space, and Nucleate UK’s founder-development ecosystem make this a particularly timely conversation.
Who should attend?
Researchers in immunology, synthetic biology, bioengineering, genomics, drug delivery, and computational biology; PhD students and postdocs exploring translation; clinicians and translational scientists; biotech founders and aspiring founders; investors, operators, and ecosystem builders interested in where the next wave of immune therapeutics may come from.
Nucleate Translate is an initiative designed to support innovators in transforming breakthrough research into deeply technical ventures within ARIA’s Opportunity Spaces via Nucleate's flagship programme, the Activator.
Nucleate Translate is powered through our partnership with the Advanced Research + Invention Agency (ARIA)
The Advanced Research + Invention Agency (ARIA) is an R&D funding agency created to unlock technological breakthroughs that benefit everyone. This seminar will provide an inside look at ARIA and its Opportunity Spaces as we delve into the unparalleled value of investing in frontier research and discovery to drive groundbreaking innovation. ARIA was established in January 2023 to create transformational impact through science and technology. With £800 million in initial funding and unmatched autonomy and flexibility, ARIA is tackling global challenges with R&D. ARIA's Programme Directors are the driving force behind this vision, each entrusted with managing a £50 million+ budget to lead ambitious, high-risk, high-reward initiatives.
Nucleate is a 501(c)(3) nonprofit organization dedicated to empowering the next generation of biotech leaders. With chapters spanning 41 geographic regions and participation from over 280 academic institutions, Nucleate sparks new intellectual communities and embeds emerging talent within a global biotech community. Through open-access educational programming, Nucleate helps democratize biotech innovation — removing barriers and helping founders concentrate on building transformational technologies. Visit www.nucleate.org for more information, and visit https://nucleate.org/privacy-policy/ to read our privacy policy.
We want to thank our HQ supporters for championing our open-access mission and empowering the next generation of biotech entrepreneurs!
https://nucleate.org/sponsors/